Medicinal Inorganic Chemistry: Using Toxicity to Advantage

Author(s):  
Katherine H. Thompson
2012 ◽  
Vol 65 (9) ◽  
pp. 1325 ◽  
Author(s):  
Nathan L. Kilah ◽  
Eric Meggers

Sixty years ago, the Australian chemist Francis P. Dwyer pioneered the use of ruthenium polypyridyl complexes as biologically active compounds. These chemically inert and configurationally stable complexes revealed an astonishing range of interesting biological activities, such as the inhibition of the enzyme acetylcholinesterase, anti-cancer activity in vivo, and bacteriostatic/bacteriocidal action. This review commemorates the sixtieth anniversary of Dwyer and co-workers’ landmark 1952 publication, summarises their broader achievements in biological inorganic chemistry, and discusses the contribution of this work to the development of modern biological and medicinal inorganic chemistry.


2020 ◽  
pp. 71-113
Author(s):  
Manish Kumar ◽  
Gyanendra Kumar ◽  
Arun Kant ◽  
Dhanraj T. Masram

2021 ◽  
Vol 99 (1) ◽  
pp. 1-9
Author(s):  
Tim Storr

Alzheimer’s disease (AD) is the most common form of dementia, and the prevalence of this currently untreatable disease is expected to rise in step with increased global life expectancy. AD is a multifaceted disorder commonly characterized by extracellular amyloid–beta (Aβ) aggregates, oxidative stress, metal ion dysregulation, and intracellular neurofibrillary tangles. This review will focus on medicinal inorganic chemistry strategies to target AD, with a focus on the Aβ peptide and its relation to metal ion dysregulation and oxidative stress. Multifunctional compounds designed to target multiple disease processes have emerged as promising therapeutic options, and recent reports detailing multifunctional metal-binding compounds, as well as discrete metal complexes, will be discussed.


Sign in / Sign up

Export Citation Format

Share Document